Introduction
============

Psoriasis is a lifelong disease that severely reduces the quality of life of patients ([@b1-mmr-19-05-3421],[@b2-mmr-19-05-3421]). Recently, psoriasis has been suggested to result from the abnormal communication between keratinocytes and immunocytes ([@b3-mmr-19-05-3421]--[@b5-mmr-19-05-3421]). It is also widely accepted that psoriasis has a strong genetic background and numerous psoriasis susceptibility long noncoding (lnc) RNAs has been identified ([@b3-mmr-19-05-3421],[@b6-mmr-19-05-3421]). Several susceptible genes of psoriasis as detected via genome-wide association analysis, RNA-sequencing (RNA-seq) or microarray comprise noncoding DNA and RNA ([@b7-mmr-19-05-3421]--[@b9-mmr-19-05-3421]); however, little is known regarding the association of specific lncRNAs in the prevalence of this disease.

LncRNAs are \>200 nucleotides and can be expressed as alternatively spliced variants; however, they cannot encode proteins ([@b10-mmr-19-05-3421]). LncRNAs include antisense, intronic, intergenic, pseudogenes and retrotransposon transcripts ([@b11-mmr-19-05-3421]). In addition, lncRNAs serve important functional roles in epigenetic, transcriptional or post-transcriptional regulation by acting on *cis* and *trans*-regulated target genes ([@b12-mmr-19-05-3421]--[@b14-mmr-19-05-3421]), and form networks of ribonucleoprotein complexes ([@b12-mmr-19-05-3421]). A total of \~1% of the mammalian genome is expressed as mRNA; however, 70--90% is transcribed into lncRNA during development ([@b11-mmr-19-05-3421],[@b15-mmr-19-05-3421],[@b16-mmr-19-05-3421]). LncRNAs serve important roles in regulating immune-mediated inflammatory disorders and autoimmunity ([@b17-mmr-19-05-3421]--[@b19-mmr-19-05-3421]). Dysregulation of lncRNAs has been studied in numerous immune diseases, including systemic lupus erythematosus ([@b20-mmr-19-05-3421]), rheumatoid arthritis ([@b21-mmr-19-05-3421]), Crohn\'s disease, ulcerative colitis ([@b22-mmr-19-05-3421]), multiple sclerosis ([@b23-mmr-19-05-3421]) and psoriasis ([@b7-mmr-19-05-3421],[@b24-mmr-19-05-3421],[@b25-mmr-19-05-3421]). This suggests that lncRNAs have crucial roles in the regulation of immune-mediated disease and contribute to the pathogenesis of psoriasis by regulating the expression of protein-coding genes, or by altering chromatin structure ([@b15-mmr-19-05-3421],[@b26-mmr-19-05-3421]).

LncRNAs are emerging as key molecules in the genesis and progression of psoriasis. Several studies have been conducted on the expression and function of lncRNAs in psoriasis; however, these studies have used RNA sequencing ([@b7-mmr-19-05-3421],[@b12-mmr-19-05-3421],[@b27-mmr-19-05-3421]). The understanding of the exact molecular mechanism is limited; no studies have performed an lncRNA microarray to investigate their expression and potential functions.

In the present study, an lncRNA microarray was performed to determine the expression profiles between psoriasis tissue and paired control tissue. In addition, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was conducted to detect 10 dysregulated lncRNAs based on the microarray results. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted to study the potential function of the differentially expressed genes. A co-expression network analysis was also performed to study molecular interactions; *cis*- and *trans*-regulated targets of lncRNAs were predicted. The results of the present study revealed that dysregulation of lncRNAs and mRNAs may contribute to the pathogenesis of psoriasis. Furthermore, lncRNAs may be used as potential biomarkers and therapeutic targets for the treatment of psoriasis.

Materials and methods
=====================

### Tissues

A total of 15 psoriasis specimens were collected from patients with psoriasis (7 males and 8 females; aged 23--39-years-old) from Qilu Hospital of Shandong University (September 2016 to August 2017). Patients did not receive systemic drugs, phototherapy or externally applied drugs during the last 3 months prior to sample collection. All tissues were obtained from the trunks; half of each tissue sample was frozen immediately at −80°C. The remaining tissue was embedded in paraffin for pathological examination. In addition, 15 normal tissues were collected from healthy volunteers (8 males and 7 females; aged 25--40-years-old) and tissue specimens were stored at −80°C; three samples of the psoriasis and normal tissues were used for microarray analysis, and the remaining 12 pairs of tissue were used for RT-qPCR. The present study was approved by the Ethics Committee of Shandong University, Qilu Hospital (Jinan, China). All patients enrolled in the present study provided written informed consent.

### LncRNA and mRNA microarray

The microarray \[SBC Human (4×180K) competing endogenous (ce)RNA microarray; Shanghai Biotechnology Corporation, Shanghai, China\] used in the present study could detect 68,432 lncRNAs and 18,853 mRNAs sourced from the most authoritative databases, including University of California Santa Cruz (<https://genome.ucsc.edu/>), GENCODE v21/Ensembl (<https://www.gencodegenes.org/human/release_21.html>), LNCipedia v3.1 ([@b28-mmr-19-05-3421]), Noncode v4 ([@b29-mmr-19-05-3421]) and Lncrnadb v2.0 ([@b30-mmr-19-05-3421],[@b31-mmr-19-05-3421]). The lncRNA and mRNA probes were designed according to the latest genome version \[human/GRCh38 (hg38)\].

### RNA extraction

Total RNAs from skin samples were extracted using an RNeasy mini kit (cat. no. 74106; Qiagen GmBH, Hilden, Germany) according to the manufacturer\'s protocols. Following this, RNA integration was investigated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA).

### RNA labelling

Total RNAs from skin samples were amplified and labeled using a Low Input Quick Amp WT Labeling kit (cat. no. 5190-2943; Agilent Technologies, Inc.) according to the manufacturer\'s protocols. Furthermore, a RNeasy mini kit (cat. no. 74106; Qiagen GmBH) was used to purify the labelled cRNAs according to the manufacturer\'s protocols.

### Cy3-labelled hybridization

The RNA of each skin sample in the present study was hybridized with 1.65 µg Cy3-labelled cRNA using a commercialized Gene Expression Hybridization kit (cat. no. 5188-5242; Agilent Technologies, Inc.) according to the manufacturer\'s protocols. Following this, the slides were washed with a Gene Expression Wash Buffer kit (cat. no. 5188-5327; Agilent Technologies, Inc.) 17 h later.

### Data analysis

Each slide was scanned using an Agilent Microarray Scanner (Dye channel, Green; Scan resolution=3 µm; photoelectric multi-plication tube 100%, 20 bit; Agilent Technologies, Inc). The experimental data were collected using Feature Extraction software 10.7 (Agilent Technologies, Inc.), which were then normalized using the limma packages in R (version 3.8) ([@b32-mmr-19-05-3421]).

### Function analysis of dysregulated genes

GO analysis was performed to detect the functions of the dysregulated genes. The KEGG database (<https://www.genome.jp/kegg/>) was used to investigate the functions of these dysregulated genes in the pathways.

### Target prediction of dysregulated lncRNAs

As previously described ([@b33-mmr-19-05-3421]), two methods were used to identify target mRNAs of dysregulated lncRNAs. Firstly, cis-acting target mRNAs were searched. Cis-target genes were considered as transcribed within a 10 kbp window upstream or downstream of lncRNAs. Furthermore, target genes were identified according to the sequence of mRNA and RNA duplex energy prediction. BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) was used in the present study for screening and parameters were set (e-value, 1e-20; identity, ≥95%). RNAplex software (<https://omictools.com/rnaplex-tool>) and starBase v3.0 (<http://starbase.sysu.edu.cn/>) were also used in the present study to screen trans-regulated predicted target mRNAs and microRNAs, respectively (e≤-30) ([@b34-mmr-19-05-3421]).

### Weighted gene co-expression network analysis

Weighted gene co-expression network analysis (WGCNA) was performed as described in previous studies ([@b35-mmr-19-05-3421],[@b36-mmr-19-05-3421]).

### RT-qPCR

Total RNA extracted from skin samples was reverse transcribed using a ReverTra Ace qPCR kit (cat. no. FSQ-101; Toyobo Life Science, Osaka, Japan) according to the manufacturer\'s protocols. The expression levels of 10 dysregulated lncRNAs in 12 psoriasis and normal control tissue samples were detected by RT-qPCR using Power SYBR-Green PCR Master Mix (cat. no. 4368708) on the 7900 HT Sequence Detection System (both Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer\'s protocols. The thermocycling conditions were as follows: Stage 1, 50°C for 2 min; stage 2, 95°C for 10 min; stage 3 (40 cycle) 95°C for 15 sec, 60°C for 1 min, and stage 4, 95°C for 15 sec, 60°C for 15 sec and 95°C for 15 sec. GAPDH was used as an internal control. The primers employed in the present study are listed in [Table I](#tI-mmr-19-05-3421){ref-type="table"}. All the experiments were repeated three times ([@b37-mmr-19-05-3421]).

### Statistical analyses

Data in the present study were presented as the mean ± standard deviation from three independent experiments. Differences between groups were analyzed using Student\'s t-test and Benjamini-Hochberg correction with SPSS 17.0 analysis software (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Dysregulated lncRNAs

To investigate the dysregulated lncRNAs in psoriasis, an lncRNA microarray analysis was performed using psoriasis lesions and normal tissue. According to the lncRNA microarray results, 2,194 lncRNAs were dysregulated (≥2.0 fold, P\<0.05). Among these lncRNAs, 1,123 lncRNAs were upregulated and 1,071 lncRNAs were downregulated ([Fig. 1A](#f1-mmr-19-05-3421){ref-type="fig"}). Hierarchical clustering analysis was used to arrange specimens in the present study according to the level of expression ([Fig. 1B](#f1-mmr-19-05-3421){ref-type="fig"}). The top 10 upregulated and downregulated lncRNAs of the microarray results were presented in [Table II](#tII-mmr-19-05-3421){ref-type="table"}. Among these, lnc-SLC6A14-1:1 (79.87306773-fold) was the most overexpressed lncRNA and NONHSAT044111 (29.0815707-fold) was the most downregulated lncRNA. The results of microarray analysis revealed that the number of upregulated lncRNAs was greater than that of downregulated lncRNAs.

### Dysregulated mRNAs

Based on the microarray results, 1,725 dysregulated mRNAs were identified. Among these, 1,157 mRNAs were overexpressed and 568 mRNAs were downregulated ([Fig. 2](#f2-mmr-19-05-3421){ref-type="fig"}). The top 10 upregulated and downregulated mRNAs were indicated ([Table III](#tIII-mmr-19-05-3421){ref-type="table"}). DEFB4A (3,505.251346 fold) was the most overexpressed lncRNA and WIF1 (32.27749933 fold) was the most downregulated lncRNA. The microarray results suggested that that there was a greater number of upregulated mRNAs.

### Function analysis of dysregulated mRNAs

To assess the pathogenesis of psoriasis, the top 30 GO terms between the psoriasis and control groups were obtained via enrichment analysis ([Fig. 3](#f3-mmr-19-05-3421){ref-type="fig"}). The association of dysregulated mRNAs with 'molecular function', 'biological processes' and 'cellular component' in the GO database was assessed. Numerous dysregulated epigenetic and genetic genes associated with 'T-helper 17 cell differentiation', 'T-cell chemotaxis', 'regulation of T-cell chemotaxis', 'keratinization', 'positive regulation of T-helper 17' and 'T-helper 1 type immune response' were identified. This suggested that a variety of specific genes were involved in the pathogenesis of psoriasis, particularly genes associated with pro-inflammatory cells and molecules.

To further investigate the pathogenesis of psoriasis, analysis of the top 30 KEGG pathways between the psoriasis and control groups was performed ([Fig. 4](#f4-mmr-19-05-3421){ref-type="fig"}). The results revealed that 23 pathways were identified to be significantly enriched (P\<0.05). The majority of these pathways were associated with inflammation and lipid metabolism, including the 'Janus kinase (Jak)-signal transducers and activators of transcription (STAT)' signaling pathway (associated with 26 genes), the 'cytokine-cytokine receptor' interaction signaling pathway (associated with 56 genes), the 'cell cycle' signaling pathway (associated with 28 genes), the 'Toll-like receptor' signaling pathway (associated with 17 genes), the 'Wnt' signaling pathway (associated with 24 genes) and the 'chemokine' signaling pathway (associated with 30 genes) (data not shown). These findings also reinforced the fact that psoriasis is a chronic, immune-mediated disorder.

### Potential targets and function of the dysregulated lncRNAs

To investigate whether the differentially expressed lncRNAs regulate genes and determine the signaling pathways associated with psoriasis, target prediction programs were used to predict the potential targets of the dysregulated lncRNAs (data not shown). It was revealed that 1,549 dysregulated lncRNAs had predicted target genes in the present study. Among these, 1,447 dysregulated lncRNAs had cis-regulated target genes, 397 dysregulated lncRNAs had trans-regulated target genes and 295 dysregulated lncRNAs had trans-and cis-regulated target genes.

Notably, 3,740 mRNAs may be regulated by the dysregulated lncRNAs. Among these, 1,460 mRNAs may be *cis*-regulated, 2,588 mRNAs may be *trans*-regulated, and 308 mRNAs may be *cis*-and *trans*-regulated. Upon further analysis and integration with the profile of differentially expressed lncRNAs, a total of 489 mRNAs were dysregulated. Furthermore, the results suggested that these mRNAs may be regulated by dysregulated *cis*- or *trans*-acting lncRNAs. Among these, 289 dysregulated mRNAs could be regulated by dysregulated *cis*-acting lncRNAs and 262 dysregulated mRNAs could be regulated by dysregulated *trans*-acting lncRNAs.

These results indicated that the dysregulated lncRNAs were involved in the onset of psoriasis by regulating their potential target mRNAs and its associated signaling pathways.

### Co-expression network of lncRNAs and mRNAs

Aided by the microarray data and a weighted gene co-expression network analysis approach, numerous networks of coordinately expressed genes were identified in psoriasis tissues compared with the normal control tissues ([Fig. 5](#f5-mmr-19-05-3421){ref-type="fig"}). The co-expression results in the present study strongly support a network model in which lncRNAs and mRNAs function together in psoriasis. Furthermore, the findings suggested that lncRNAs do not act alone but rather work in concert with other lncRNAs and mRNAs.

### RT-qPCR analysis

In order to detect the lncRNA and mRNA microarray results, 10 dysregulated lncRNAs were randomly selected for RT-qPCR analysis. Based on the results of the microarray data, 6 upregulated lncRNAs (lnc-AP000769.1--1:2, NONHSAT066260, lnc-PXDNL-4:1, ENST00000557691, lnc-HSFY2-10:1 and ENST00000547006) and 4 downregulated lncRNAs (lnc-MGMT-2:1, lnc-POLR3E-3:3, lnc-THRSP-6:1 and lnc-PERP-2:7) were selected.

The expression levels of dysregulated lncRNAs were validated by RT-qPCR (n=12). The expression levels of 7 lncRNAs were consistent with the microarray results, which exhibited the same dysregulation profiles (up-/down-regulated, ≥2.0 fold) ([Fig. 6A](#f6-mmr-19-05-3421){ref-type="fig"}). Of note, 3 lncRNAs (lnc-AP000769.1-1:2, ENST00000557691 and lnc-HSFY2-10:1) were upregulated and 4 lncRNAs (lnc-MGMT-2:1, lnc-POLR3E-3:3, lnc-THRSP-6:1 and lnc-PERP-2:7) were downregulated (≥2.0 fold) ([Fig. 6A](#f6-mmr-19-05-3421){ref-type="fig"}). The expression levels of lnc-MGMT-2:1 (P\<0.05), lnc-AP000769.1-1:2 (P\<0.05) and lnc-HSFY2-10:1 (P\<0.01) were significantly different between the psoriasis and normal tissues ([Fig. 6B](#f6-mmr-19-05-3421){ref-type="fig"}); however, lnc-PXDNL-4:1 was observed to be downregulated, and the expression levels of NONHSAT066260 and ENST00000547006 in psoriasis and normal tissues exhibited 0.5\<fold change\<2 ([Fig. 6B](#f6-mmr-19-05-3421){ref-type="fig"}).

Discussion
==========

It is well known that psoriasis has a strong genetic predisposition ([@b38-mmr-19-05-3421]--[@b40-mmr-19-05-3421]); however, the underlying genetic mechanisms remain unknown. Previous transcriptomic studies in psoriasis have analyzed the expression levels of mRNA to investigate the functions of their translated proteins, including protein-coding genes associated with the interleukin-17 signaling pathway ([@b41-mmr-19-05-3421]), the nuclear factor (NF)-κB signaling pathway ([@b42-mmr-19-05-3421],[@b43-mmr-19-05-3421]), the Jak-STAT signaling pathway ([@b44-mmr-19-05-3421]) and the mitogen-activated protein kinase (MAPK) signaling pathway ([@b45-mmr-19-05-3421],[@b46-mmr-19-05-3421]).

LncRNAs were once considered as transcriptional noise or junk but have recently begun to attract attention in research ([@b15-mmr-19-05-3421],[@b47-mmr-19-05-3421]). LncRNAs serve important roles in regulating various functions of the immune system ([@b18-mmr-19-05-3421],[@b48-mmr-19-05-3421],[@b49-mmr-19-05-3421]). Increasing evidence suggests lncRNA dysregulation may have a vital role in the pathogenesis of psoriasis ([@b8-mmr-19-05-3421],[@b25-mmr-19-05-3421],[@b50-mmr-19-05-3421]). At present, few lncRNAs associated with psoriasis have been investigated. Psoriasis associated non-protein coding RNA induced by stress (PRINS), an lncRNA gene, exhibited the highest expression levels in non-psoriatic skin lesions, indicating that it may serve an important role in the susceptibility of psoriasis ([@b51-mmr-19-05-3421]). Széll *et al* ([@b25-mmr-19-05-3421]) reported that overexpression of PRINS in non-lesional psoriatic skin alters the stress response and contributes to disease pathogenesis. Furthermore, Szegedi *et al* ([@b52-mmr-19-05-3421]) reported that the dysregulation of PRINS contributed to the onset of psoriasis, resulting in decreased keratinocyte apoptosis. Another lncRNA gene associated with psoriasis, psoriasis susceptibility 1 candidate 3, has been considered to be strongly associated with psoriasis ([@b53-mmr-19-05-3421]). Using RNA-seq, Kretz *et al* ([@b54-mmr-19-05-3421]) reported terminal differentiation-induced lncRNA, which controls human epidermal differentiation via posttranscriptional regulation. Therefore, similar to mRNAs, lncRNAs may function as proinflammatory or inducers of proliferation in psoriasis by regulating transcriptional regulation or altering the expression levels of their target mRNAs.

To the best of our knowledge, the present study is the first to determine lncRNA and mRNA expression profiles in psoriasis compared with normal healthy volunteers using a microarray. GO and KEGG pathway analyses were conducted to determine the potential functions and co-expression networks of lncRNAs to study the molecular interactions.

To validate the microarray results and predict the possible role of lncRNAs in psoriasis, 10 dysregulated lncRNAs were randomly selected for RT-qPCR analysis. The results of RT-qPCR were consistent with the data of microarray results: 3 lncRNAs (lnc-AP000769.1-1:2, ENST00000557691 and lnc-HSFY2-10:1) were upregulated and 4 lncRNAs (lnc-MGMT-2:1, lnc-POLR3E-3:3, lnc-THRSP-6:1 and lnc-PERP-2:7) were downregulated. By predicting *cis*- and *trans*-acting lncRNAs, it was revealed that lnc-AP000769.1-1:2 (upregulated) and lnc-MGMT-2:1 (downregulated) have a common predicted target gene, *jak3*, which suggested they may be involved in the pathogenesis of psoriasis by regulating *jak3*. ENST00000557691 (upregulated) and lnc-PERP-2:7 (downregulated) may regulate the MAPK signaling pathway by regulating their predicted target gene, *mapk kinase kinase 9*. Lnc-HSFY2-10:1 (upregulated) was predicted to regulate microRNA-145 (starBase v3.0). Of note, it has been reported that miR-145 negatively regulates cell proliferation and proinflammatory cytokine release, and inhibits the downstream genes of NF-κB and mechanistic target of rapamycin (mTOR) ([@b55-mmr-19-05-3421],[@b56-mmr-19-05-3421]). Thus, lnc-HSFY2-10:1 may be involved in the pathogenesis of psoriasis via ceRNA regulation. Lnc-POLR3E-3:3 (downregulated), which possibly regulates interferon regulatory factor 1 (*irf1*) in *trans*, may be involved in regulating T regulatory (Treg) cell differentiation, as *irf1* has been considered as a regulator of Treg cells by inhibiting Forkhead box P3 in mice ([@b57-mmr-19-05-3421]). Lnc-THRSP-6:1, which has been predicted to potentially regulate C-C motif chemokine ligand 5 (*ccl5*) (data not shown) via RNAplex software, was downregulated in the present study. This suggested that the predicted target gene proinflammation chemokine, *ccl5*, may be overexpressed and that lnc-THRSP-6:1 contributes to the pathogenesis of psoriasis. However, the expression levels of lnc-PXDNL-4:1, as determined by RT-qPCR, were not in agreement with the results of microarray analysis in the present study. The lncRNA and mRNA probes were designed according to the latest genome version \[human/GRCh38 (hg38)\] and the primers were carefully selected; thus, this discrepancy may be due to the small sample size (n=12). This suggests that further investigation using a larger sample is required. In addition, the expression levels of NONHSAT066260 and ENST00000547006 were not significantly different, which indicated that they may not be involved in the onset of psoriasis.

The results microarray and RT-qPCR analyses suggested that lncRNAs were involved in the pathogenesis of psoriasis, possibly by regulating the differentiation and function of Treg cells, the NF-κΒ signaling pathway, the mTOR signaling pathway and the MAPK signaling pathway, the release of cytokines and chemokines, and the JAK-STAT signaling pathway.

GO and KEGG analyses were performed to investigate the biological functions that were enriched among the dysregulated mRNAs. GO analysis identified 'T-helper 17 cell differentiation', 'T-cell chemotaxis' and the 'T-helper 17 type immune response' to be involved in the development of psoriasis. In addition, pathway analysis identified several pathways associated with psoriasis, including the 'JAK-STAT' signaling pathway, the 'cytokine-cytokine' receptor interaction signaling pathway, the 'cell cycle' signaling pathway, the 'Wnt' signaling pathway and the 'MAPK' signaling pathway. These results further supported the data obtained from the microarray analysis.

Co-expression analyses emphasized the importance of integrating the expression profiles of lncRNA and mRNA to obtain more generalized information. Genes with strong associations are more likely to be co-regulated with their co-expressed genes ([@b58-mmr-19-05-3421]). The results of the co-expression analyses indicated that the dysregulated lncRNA may collaboratively function the pathogenesis of psoriasis.

In addition, it is well reported that the detection of lncRNAs on the array platform is more stable than RNA-seq ([@b59-mmr-19-05-3421],[@b60-mmr-19-05-3421]). Therefore, the study of lncRNA and mRNA microarray expression in psoriasis is valuable and may improve the understanding of the pathogenesis of psoriasis.

In conclusion, to the best of our knowledge, the present study is the first to conduct a microarray to investigate lncRNA expression in psoriasis. The findings also revealed that numerous lncRNAs were dysregulated in psoriasis; several networks of mRNA and lncRNA were associated with the pathogenesis of psoriasis, including pathways that have not been previously identified. RT-qPCR, target prediction and co-expression analyses revealed that the lncRNAs did not act alone, but rather functioned in concert with other lncRNAs, which may facilitate the development of psoriasis. Despite the limitations of the present study, including the small sample size, and that no functional or mechanical investigations using the biopsies were conducted, the results may provide insight for further into the development and treatment of psoriasis.
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![Analysis of top 30 Gene Ontology terms between the psoriasis and control groups. The rich factor was calculated using the number of enriched genes divided by the number of all background genes in the corresponding pathway. P-values were calculated using Benjamini-Hochberg correction. P\<0.05 was considered to indicate statistically significant over-representation.](MMR-19-05-3421-g02){#f3-mmr-19-05-3421}
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![Analysis of lncRNA-mRNA co-expression in psoriasis. Red represented upregulated genes; green represented downregulated genes; circles represented target mRNA; squares represented lncRNAs; the solid line represented trans regulation; and the dotted line represented cis regulation. The sizes of the circles/squares indicate the number of associated genes correlated. LncRNAs, long noncoding RNAs.](MMR-19-05-3421-g04){#f5-mmr-19-05-3421}

![Results of RT-qPCR. (A) Comparison of fold change \[log2 (Nor/Ps)\] of lncRNAs between microarray and RT-qPCR results. (B) Relative expression levels of lncRNAs in 12 pairs of Nor and Ps tissue. The expression levels of lncRNA were calculated using the 2^−ΔΔCq^ method, and the results are presented as relative fold changes. Data are expressed as the mean ± standard deviation. Comparisons between two groups were performed using a Student\'s t test. \*P\<0.05 and \*\*P\<0.01 vs. Nor. Nor, normal control; Ps, psoriasis; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; lncRNAs, long noncoding RNAs.](MMR-19-05-3421-g05){#f6-mmr-19-05-3421}

###### 

Primers used for reverse transcription-quantitative polymerase chain reaction.

  LncRNA, mRNA or gene   Forward primer (5′-3′)   Reverse primer (5′-3′)
  ---------------------- ------------------------ ---------------------------
  ENST00000547006        CATTGTTGCTTTTCGGGTCT     GGCCACGTAGCAATGACTGT
  lnc-HSFY2-10:1         ACCCACGCAGATTTATTCCA     CCTTGGTGGTGGCATTAGTT
  lnc-PERP-2:7           CCATTTTTCTGTGGTCAGGTC    GCTGTTGAAGAGCACTGTGAG
  ENST00000557691        CATGCTGAGTCTGCAAGGAC     CAAAAACCCCGATGATAGGA
  lnc-THRSP-6:1          GTTCCATTGATCCAGCCACT     ACAAGAGGCCACTGACTGCT
  NONHSAT066260          CACTGCACTTGGCTGTGATT     GGCCGAGAAGCCTAGAAGAA
  lnc-MGMT-2:1           GGAAAAACACAGCAGCCAGT     ACGCCAACACCCTGTAGACT
  lnc-AP000769.1-1:2     CACCAGCTTCTCCAATCTTCCT   GGAGTAAGCAAGTCACAATGTTGAG
  lnc-POLR3E-3:3         TACTGAGAATGGGGAAGGAAAC   CTCTTGCTTACTGCCTGCTGA
  lnc-PXDNL-4:1          CAGGTCAGGCTGTTGGATTCT    AGGATGTGCTTCTTGGGAGTC
  GAPDH                  TGACTTCAACAGCGACACCCA    CACCCTGTTGCTGTAGCCAAA

LncRNA, long noncoding RNA.

###### 

Top 10 differentially expressed lncRNAs in psoriasis tissues compared with normal control.

  A, Upregulated lncRNAs                                         
  ------------------------------ ------------- ----------------- ------------
  lnc-SLC6A14-1:1                0.00292       79.87             LNCipedia
  NR_003062                      0.00114       55.64             RefSeq
  lnc-SERPINB3-4:1               0.00113       48.26             LNCipedia
  NONHSAT006518                  0.00775       38.64             NONCODE
  lnc-IGFL3-6:1                  0.00096       37.3              LNCipedia
  ENST00000472053                0.00687       36.05             ENSEMBL
  NONHSAT006509                  0.01240       30.2              NONCODE
  NR_030617                      0.00942       25.21             RefSeq
  lnc-RAPGEF2-3:1                0.00427       25.13             LNCipedia
  lnc-RPP40-3:3                  0.00719       24.61             LNCipedia
                                                                 
  **B, Downregulated lncRNAs**                                   
                                                                 
  **LncRNA**                     **P-value**   **Fold change**   **Source**
                                                                 
  NONHSAT044111                  0.0344        29.08             NONCODE
  lnc-PPM1N-1:1                  0.0600        16.66             LNCipedia
  lnc-GRHL2-11:1                 0.0692        14.45             LNCipedia
  lnc-JAKMIP2-1:1                0.0704        14.21             LNCipedia
  lnc-GGTLC1-2:1                 0.0734        13.62             LNCipedia
  NONHSAT025181                  0.0799        12.52             NONCODE
  ENST00000447257                0.0832        12.01             ENSEMBL
  ENST00000623414                0.0843        11.863            ENSEMBL
  ENST00000415656                0.0943        10.61             ENSEMBL
  lnc-LINC00273-22:1             0.0959        10.43             LNCipedia

LncRNA, long noncoding RNA.

###### 

Top 10 differentially expressed mRNAs in psoriasis tissues compared with normal control.

  A, Upregulated mRNAs                                         
  ---------------------------- ------------- ----------------- ------------
  DEFB4A                       0.00016       3505.25           RefSeq
  SERPINB4                     0.00967       780.42            RefSeq
  S100A7A                      0.00840       672.76            RefSeq
  S100A12                      0.00029       582.68            RefSeq
  PI3                          0.00315       199.59            RefSeq
  SERPINB3                     0.00314       180.61            RefSeq
  SPRR2G                       0.00420       162.24            RefSeq
  S100A9                       0.02130       159.63            RefSeq
  LCE3A                        0.00102       152.00            RefSeq
  IL36A                        0.00276       149.66            RefSeq
                                                               
  **B, Downregulated mRNAs**                                   
                                                               
  **mRNA**                     **P-value**   **Fold change**   **Source**
                                                               
  WIF1                         0.0310        32.28             RefSeq
  MT4                          0.0322        31.05             RefSeq
  BTC                          0.0333        30.05             RefSeq
  CACNA1H                      0.0457        21.87             RefSeq
  CYP2W1                       0.0470        21.29             RefSeq
  KRT77                        0.0615        16.27             RefSeq
  FAM166B                      0.0617        16.20             RefSeq
  NEUROD2                      0.0671        14.90             RefSeq
  SPINK1                       0.0693        32.28             RefSeq
  ZBTB16                       0.0780        31.05             RefSeq

[^1]: Contributed equally
